Major cardiovascular events increase in long-term proprotein convertase subtilisin/kexin type 9 inhibitors therapy: the Tuscany cost-effective study

Inclisiran and lipoprotein apheresis in statin intolerance heterozygous FH patients: A case series

(2023) Beatrice Dal Pino et al.   THERAPEUTIC APHERESIS AND DIALYSIS

International Union of Angiology (IUA) consensus paper on imaging strategies in atherosclerotic carotid artery imaging: From basic strategies to advanced approaches

(2022) Luca Saba et al.   ATHEROSCLEROSIS

Screening, diagnosis, and treatment of familial hypercholesterolaemia: a call to action

(2022) Filippo Crea   EUROPEAN HEART JOURNAL

Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat

(2022) Hong-Fei Wang et al.   Frontiers in Cardiovascular Medicine

Acute coronary syndrome and lipid-lowering therapy in a realistic diagnostic-therapeutic care pathway

(2021) Tiziana Sampietro et al.   PHARMACOLOGICAL RESEARCH

Is treating severe He FH so easy? A combined treatment between lipoprotein apheresis and PCSK9 inhibitors

(2021) Beatrice Dal Pino et al.   TRANSFUSION AND APHERESIS SCIENCE

Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study

(2021) David Nanchen et al.   ADVANCES IN THERAPY

PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort

(2021) Juan Vicente-Valor et al.   BIOMEDICINE & PHARMACOTHERAPY

Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world study

(2021) Gabriella Iannuzzo et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: a retrospective, single center, observational study

(2020) Laura D’Erasmo et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real‐life setting: the PROSISA Study

(2020) M. Casula et al.   JOURNAL OF INTERNAL MEDICINE

PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies

(2019) Massimiliano Ruscica et al.   European Journal of Preventive Cardiology

Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis

(2019) Ralf Spitthöver et al.   JOURNAL OF CLINICAL APHERESIS

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

A large Italian cohort on proprotein convertase subtilisin/kexin type 9 inhibitors

(2019) Francesco Sbrana et al.   European Journal of Preventive Cardiology

PCSK9 Inhibitors’ New Users: Analysis of Prescription Patterns and Patients’ Characteristics from an Italian Real-world Study

(2019) Carlo Piccinni et al.   CLINICAL DRUG INVESTIGATION

Elusive Therapeutic Effect of PCSK9 Inhibitors on Lipoprotein(a) Levels

(2018) Francesco Sbrana et al.   THERAPEUTIC APHERESIS AND DIALYSIS

Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?

(2017) Francesco Sbrana et al.   European Journal of Preventive Cardiology

Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors

(2017) Ivan Pećin et al.   European Journal of Preventive Cardiology

Association Between Achieved Low-Density Lipoprotein Levels and Major Adverse Cardiac Events in Patients With Stable Ischemic Heart Disease Taking Statin Treatment

(2016) Morton Leibowitz et al.   JAMA Internal Medicine